Program
Albumin-Bound Paclitaxel
Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.
Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.
Drug pageAlbumin-Bound Paclitaxel: every studyMany companies study it; this page follows only the 51 they lead. All 527 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 380 open or running | phase 4since May 28, 2014 | Sep 30, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 31 open or running | phase 3since Aug 15, 2017 | Aug 15, 2017 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| Astellas Pharmaits history only | 10 open or running | phase 1since Nov 6, 2009 | Nov 6, 2009 | none ahead |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Lee's Pharmaceuticalits history only | 10 open or running | phase 1since Sep 8, 2020 | Sep 8, 2020 | none ahead |
| Novartisits history only | 10 open or running | phase 2since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| NovoCureits history only | 10 open or running | phase 2since Feb 29, 2024 | Feb 29, 2024 | none ahead |
| Otsukaits history only | 10 open or running | phase 2since Apr 16, 2008 | Apr 16, 2008 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 36 studies since Sep 30, 2002.
- Oct 1, 2014Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02267707 · 1 enrolled · United States, Germany
- Nov 10, 20142 phase 2 studiesBristol-Myers Squibb · NCT02289456, NCT02301143
- Dec 3, 2014Phase 1 study in Breast NeoplasmsBristol-Myers Squibb · NCT02309177 · 114 enrolled · United States
- Dec 18, 2014SynerGene Therapeutics’ first study: phase 2 study in Pancreatic NeoplasmsNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02340117 · 28 enrolled · United States
- Nov 30, 2015Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02620800 · 12 enrolled · United States
- Mar 24, 2016Academic Thoracic Oncology Medical Investigators Consortium’s first study: phase 2 study in Pancreatic NeoplasmsNew to Academic Thoracic Oncology Medical Investigators ConsortiumAcademic Thoracic Oncology Medical Investigators Consortium · NCT02723331 · 48 enrolled · United States
- Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
- Aug 15, 2017CSPC Pharmaceutical Group’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03262948 · 388 enrolled
- Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
- Sep 8, 2020Lee's Pharmaceutical’s first study: phase 1 study in Advanced Urothelial CarcinomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04603846 · 20 enrolled · China
- May 10, 2021EBG MedAustron’s first study: no phase study in Pancreatic NeoplasmsNew to EBG MedAustronEBG MedAustron · NCT04894643 · 10 planned · Austria
- Apr 12, 2022Phase 1 study in Advanced Solid TumorCSPC Pharmaceutical Group · NCT05344742 · 116 enrolled
- Feb 29, 2024NovoCure’s first study: phase 2 study in Pancreatic NeoplasmsNew to NovoCureNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
- Jul 24, 2025Phase 1 study in BioequivalenceCSPC Pharmaceutical Group · NCT07096869 · 28 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Pancreatic NeoplasmsSynerGene Therapeutics · NCT02340117
- Dec 31, 2026Primary completion: no phase study in Pancreatic NeoplasmsEBG MedAustron · NCT04894643
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 51 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07096869Bioequivalence · China | 1 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2025 | 28 |
| NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more | 2 | Completed | NovoCure | Nov 18, 2025 | 84 |
| NCT05344742Advanced Solid Tumor | 1 | UNKNOWN | CSPC Pharmaceutical Group | Mar 2024 | 116 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | EBG MedAustron | Dec 31, 2026 | 10 |
| NCT04603846Advanced Urothelial Carcinoma · China | 1 | UNKNOWN | Lee's Pharmaceutical | Oct 1, 2022 | 20 |
| NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 205 |
| NCT03262948Carcinoma, Non-Small-Cell Lung | 3 | UNKNOWN | CSPC Pharmaceutical Group | Oct 1, 2019 | 388 |
| NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2023 | 332 |
| NCT02723331Pancreatic Neoplasms · United States | 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | Dec 8, 2022 | 48 |
| NCT02620800Pancreatic Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | Oct 29, 2018 | 12 |
| NCT02340117Pancreatic Neoplasms · United States | 2 | Active, not recruiting | SynerGene Therapeutics | Dec 2026 | 28 |
| NCT02309177Breast Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | Sep 12, 2018 | 114 |
| NCT02301143Pancreatic Neoplasms · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Nov 21, 2017 | 107 |
| NCT02289456Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | Feb 22, 2017 | 40 |
| NCT02267707Pancreatic Neoplasms · United States, Germany | 1 | Terminated | Bristol-Myers Squibb | Feb 10, 2016 | 1 |
| NCT02250326Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Jul 17, 2017 | 240 |
| NCT02151149Carcinoma, Non-Small-Cell Lung · United States | 4 | Completed | Bristol-Myers Squibb | Jul 14, 2017 | 143 |
| NCT02103062Colorectal Neoplasms · France | 2 | Completed | Bristol-Myers Squibb | Nov 10, 2014 | 41 |
| NCT02045602Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | May 2019 | 42 |
| NCT02045589Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | Oct 2016 | 8 |
| NCT02027428Carcinoma, Squamous Cell · United States, Germany, Italy and more | 3 | Completed | Bristol-Myers Squibb | Sep 15, 2017 | 427 |
| NCT02017015Pancreatic Neoplasms · China | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2015 | 83 |
| NCT01964430Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jun 30, 2022 | 866 |
| NCT01962103Neuroblastoma · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Dec 5, 2017 | 107 |
| NCT01933061Melanoma | 2 | Withdrawn | Bristol-Myers Squibb | Jan 2014 | 0 |
| NCT01881230Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Oct 28, 2016 | 191 |
| NCT01010945Adenocarcinoma · United States | 1 | Completed | Astellas Pharma | Jan 25, 2012 | 19 |
| NCT00864253Melanoma · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jun 1, 2012 | 529 |
| NCT00844649Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Sep 17, 2012 | 861 |
| NCT00709761Breast Neoplasms · United States | 2 | Completed | Novartis | Jan 5, 2011 | 60 |
| NCT00661167Stomach Neoplasms · Japan | 2 | Completed | Otsuka | May 2011 | 56 |
| NCT00540514Carcinoma, Non-Small-Cell Lung · United States, Canada | 3 | Completed | Bristol-Myers Squibb | Oct 1, 2009 | 1,052 |
| NCT00518284Peripheral Vascular Diseases · United States | 2 | Terminated | Bristol-Myers Squibb | Aug 2009 | 6 |
| NCT00456846Breast Neoplasms · Canada | 2 | Terminated | Bristol-Myers Squibb | Dec 11, 2012 | 123 |
| NCT00407407Fallopian Tube Neoplasms · United States | 1 | Terminated | Bristol-Myers Squibb | Feb 1, 2008 | 6 |
| NCT00398086Pancreatic Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2008 | 67 |
| NCT00394251Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Mar 1, 2007 | 197 |
| NCT00394082Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2009 | 50 |
| NCT00281528Breast Neoplasms · United States, Puerto Rico | 2 | Terminated | Bristol-Myers Squibb | Jul 1, 2010 | 208 |
| NCT00274456Breast Neoplasms · Ukraine | 2 | Completed | Bristol-Myers Squibb | Mar 1, 2008 | 302 |
| NCT00274443Carcinoma, Non-Small-Cell Lung · Russian Federation | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2007 | 250 |
| NCT00249002Hemodialysis Graft Dysfunction · United States | 2 | Terminated | Bristol-Myers Squibb | Nov 1, 2007 | 9 |
| NCT00140140Neoplasm Metastasis · United States | 2 | Terminated | Bristol-Myers Squibb | Feb 2008 | 16 |
| NCT00124943Coronary Restenosis | 2 | Completed | Bristol-Myers Squibb | Aug 2009 | 112 |
| NCT00107094Breast Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | 30 | |
| NCT00093145Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Oct 1, 2008 | 32 |
| NCT00093119Melanoma · United States | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 75 |
| NCT00073723Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | 75 | |
| NCT00046527Breast Neoplasms · United States | 3 | Completed | Bristol-Myers Squibb | 460 | |
| NCT00046514Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 100 | |
| NCT00046423Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | 20 |
How it is read
Names in the registry
- “ABI-007”, 15 entries
- “nab-paclitaxel”, 13 entries
- “Nab-paclitaxel”, 12 entries
- “Nab-Paclitaxel”, 9 entries
- “nab-Paclitaxel”, 6 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 24 studies
- Breast Neoplasms, 14 studies
- Carcinoma, Non-Small-Cell Lung, 11 studies
- Triple Negative Breast Neoplasms, 4 studies
- Melanoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.